Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS -0.18%60 3-Year EBITDA Growth Rate is 8.90% as of Mar. 2026, which is 39% below its 10-year median of 14.55. GuruFocus rates XSWX:ZTS with a GF Score™ of 60/100 and a GF Value™ of CHF157.68 (Significantly Undervalued). Among 813 Drug Manufacturers companies, Zoetis ranks better than 50.43% on this metric.
During the past 12 months, Zoetis's average EBITDA Per Share Growth Rate was 7.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zoetis was 677.80% per year. The lowest was -2.80% per year. And the median was 14.55% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Zoetis 3-Year EBITDA Growth Rate Related Terms
XSWX:ZTS vs UTHR, VTRS, NBIX: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Zoetis's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.90% mean?
Zoetis (XSWX:ZTS) has a 3-Year EBITDA Growth Rate of 8.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zoetis and its competitors. This is 39% below median its historical median of 14.55. According to the industry distribution chart, Zoetis ranks #403 out of 813 companies in the Drug Manufacturers industry, placing it in the top 49.6%.
Is Zoetis' 3-Year EBITDA Growth Rate too high?
Zoetis' current 3-Year EBITDA Growth Rate of 8.90% is 39% below median its 10-year median of 14.55. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Zoetis' value of 8.90% is 0% at this industry median. Based on the distribution chart, Zoetis ranks #403 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' 3-Year EBITDA Growth Rate compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #403 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Zoetis in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Zoetis' value of 8.90% is 0% at this benchmark. While the company's 10-year median is 14.55 vs. the industry median of 8.90, Zoetis has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current 3-Year EBITDA Growth Rate of 8.90% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zoetis and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current 3-Year EBITDA Growth Rate is 8.90%, which is 39% below median its own 10-year median of 14.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF157.68, compared to a current price of CHF61.68 — trading 60.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.90%, which is 39% below median its 10-year median of 14.55 and 0% at the Drug Manufacturers industry median of 8.90. Zoetis' overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current 3-Year EBITDA Growth Rate is 8.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.68 is trading 60.9% below its estimated GF Value™ of CHF157.68.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
3-Year EBITDA Growth Rate: 8.90% (39% below median its 10-year median of 14.55)
GF Value™: CHF157.68 vs. price of CHF61.68 (60.9% below fair value)
Industry Position: 0% at the Drug Manufacturers median (#403 of 813)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
60GF Score
Get the complete analysis for XSWX:ZTS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
